Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Geriatric MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Polypharmacy: evaluating risks and deprescribing.Am Fam Physician. 2019; 100: 32-38
- Breast cancer, placing drug interactions in the spotlight: is polypharmacy the cause of everything?.Clin Transl Oncol. 2021; 23: 65-73
- Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: a systematic review and meta-analysis.Oncologist. 2020; 25: e94-e108
- Polypharmacy and adherence to adjuvant endocrine therapy for breast cancer.J Oncol Pract. 2017; 13: e451-e462
- The use and concurrent use of side effect controlling medications among women on aromatase inhibitors.J Womens Health (Larchmt). 2021; 30: 131-136
- Complementary therapy use among older cancer patients.Cancer Pract. 1999; 7: 136-144
- Comorbidity and polypharmacy in patients with breast cancer.Breast Cancer. 2020; 27: 477-482
- Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer.J Clin Oncol. 2007; 25: 3837-3845
- Polypharmacy and the management of the older cancer patient.Ann Oncol. 2013; 24: vii36-vii40
- Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.J Clin Psychiatry. 2009; 70: 1688-1697
- Effect of age on drug metabolism in women with breast cancer.Expert Opin Drug Metab Toxicol. 2015; 11: 757-766
- Real-world direct health care costs associated with psychotropic polypharmacy among adults with common cancer types in the United States.J Manag Care Spec Pharm. 2019; 25: 555-565
- Cancer statistics, 2020.CA Cancer J Clin. 2020; 70: 7-30
- Prognostic factors and risk stratification in chronic lymphocytic leukemia.Semin Oncol. 2016; 43: 233-240
- Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia.N Engl J Med. 2015; 373: 2425-2437
- Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects.Front Cell Dev Biol. 2021; 9: 630942
- Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial.J Clin Oncol. 2021; 39: 3441-3452
- Risk of major bleeding with ibrutinib.Clin Lymphoma Myeloma Leuk. 2018; 18: 755-761
- Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.Blood. 2021; 137: 3165-3173
- Cancer facts & figures 2021.American Cancer Society, Atlanta2021
- Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment.J Am Geriatr Soc. 2014; 62: 1505-1512
- SIOG2021-0124 - association of polypharmacy with colorectal cancer survival among older patients.J Geriatr Oncol. 2021; 12: S59
- Impact of polypharmacy for chronic ailments in colon cancer patients: a review focused on drug repurposing.Cancers (Basel). 2020; 12: 2724
- Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: implications for the oncoprotein c-MYC.Am J Physiol Cell Physiol. 2017; 312: C176-C189
- Aspirin enhances the sensitivity of colon cancer cells to cisplatin by abrogating the binding of NF-κB to the COX-2 promoter.Aging (Albany NY). 2020; 12: 611-627
- Use of antibiotics and risk of cancer: a systematic review and meta-analysis of observational studies.Cancers (Basel). 2019; 11: 1174
- Outcomes of metastatic colorectal cancer patients in relationship to prior and concurrent antibiotics use; individual patient data analysis of three clinical trials.Clin Transl Oncol. 2020; 22: 1651-1656
- Antidepressant fluoxetine and its potential against colon tumors.World J Gastrointest Oncol. 2014; 6: 11-21
- Discovery and validation of the antimetastatic activity of citalopram in colorectal cancer.Mol Cell Oncol. 2015; 2: e975080
- Mirtazapine inhibits tumor growth via immune response and serotonergic system.PLoS One. 2012; 7: e38886
- Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus.J Clin Endocrinol Metab. 2012; 97: E1170-E1175
- Investigating metformin for cancer prevention and treatment: the end of the beginning.Cancer Discov. 2012; 2: 778-790
- Drug-Drug interactions and pharmacogenomic evaluation in colorectal cancer patients: the new drug-PIN(®) system comprehensive approach.Pharmaceuticals (Basel). 2021; 14
- SEER cancer stat facts: lung and bronchus cancer. National Cancer Institute. Bethesda, MD.(Available at:) (Accessed January 24, 2022)
- American geriatrics society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults.J Am Geriatr Soc. 2019; 67: 674-694
- Potential medication-related problems in older breast, colon, and lung cancer patients in the United States.Cancer Epidemiol Biomarkers Prev. 2018; 27: 41-49
- Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.J Cancer Res Clin Oncol. 2020; 146: 2659-2668
- Anti-dementia and anti-hyperlipidemic medication use at end of life in elderly lung cancer patients: analysis of SEER-Medicare data.J Clin Oncol. 2017; 35
- Relationship between polypharmacy and inpatient hospitalization among older adults with cancer treated with intravenous chemotherapy.J Geriatr Oncol. 2020; 11: 579-585
- Systemic anticancer therapy (SACT) for lung cancer and its potential for interactions with other medicines.Ecancermedicalscience. 2017; 11: 764
- Erlotinib in lung cancer — molecular and clinical predictors of outcome.N Engl J Med. 2005; 353: 133-144
- Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer.N Engl J Med. 2017; 378: 113-125
- Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?.Clin Pharmacol Ther. 2012; 92: 203-213
- The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer.Cancer. 2019; 125: 1155-1162
- Facts & figures 2022.American Cancer Society, Atlanta, GA2022 (Accessed)
- SEER cancer stat facts: prostate cancer.(Available at:) (Accessed February 15, 2022)
- Management of prostate cancer in the elderly.Clin Geriatr Med. 2016; 32: 113-132
- Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality.Cancer. 2012; 118: 3062-3070
- Pharmacokinetic drug-drug interactions with drugs approved by the us food and drug administration in 2020: mechanistic understanding and clinical recommendations.Drug Metab Dispos. 2022; 50: 1-7
NCCN Clinical Practice Guidelines in Oncology – Prostate Cancer. Version 1.2022. Accessed.
- Drug-drug interactions in prostate cancer treatment.Clin Genitourin Cancer. 2020; 18: e71-e82
- The role of drug-drug interactions in prostate cancer treatment: focus on abiraterone acetate/prednisone and enzalutamide.Cancer Treat Rev. 2017; 55: 71-82
- Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice.Expert Opin Drug Metab Toxicol. 2021; 17: 1467-1473
- Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: results from clinical and in vitro studies.J Clin Oncol. 2019; 37: 297
- Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial.Target Oncol. 2019; 14: 527-539
Article info
Publication history
Published online: September 13, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
